Yong Chen1,2, Tongtong Wang1, Xinyue Liu1, R Ravi Shankar3. 1. Department of Pharmacoepidemiology, Merck & Co., Inc., Kenilworth, New Jersey. 2. Department of Patient & Health Impact, Pfizer Inc., Collegeville, Pennsylvania. 3. Department of Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey.
Abstract
OBJECTIVES: To estimate the prevalence of type 1 (T1DM) and type 2 diabetes mellitus (T2DM) among U.S. Medicaid pediatric population aged <18 years 2002 to 2016 by age, sex, and race/ethnicity. METHODS: Participants aged <18 years old from 2002 to 2016 were identified from the MarketScan Multi-State Medicaid Database. Diabetes was defined as having (a) ≥1 claims for an outpatient or inpatient diabetes diagnosis and ≥2 prescriptions for any anti-diabetes medications or (b) records of ≥2 claims for an outpatient or inpatient diabetes diagnosis that were at least 30 days apart. Annual prevalence of diabetes and 95% confidence intervals (CIs) were calculated. Age-, sex-, and race-stratified prevalence were also assessed. RESULTS: The annual prevalence of T1DM increased from 1.29 to 2.34/1000 pediatric persons from 2002 to 2016. The prevalence of T2DM rose from 0.70 in 2002 to 2.76/1000 in 2011, but then dropped to 2.12/1000 pediatric persons in 2016 in the Medicaid population. Prevalence of both T1DM and T2DM increased with age. While the prevalence of T1DM was similar in both sexes, and was most prevalent in Whites, prevalence of T2DM was higher in girls and was most prevalent in Blacks. CONCLUSIONS: While the annual prevalence of T1DM in pediatric persons enrolled in Medicaid increased continuously from 2002 to 2016, the annual prevalence of T2DM increased from 2002 to 2011, with a subsequent decrease in 2016, possibly because of the increase of relatively healthier participants with the expanded eligibility through the ACA between 2011 and 2016.
OBJECTIVES: To estimate the prevalence of type 1 (T1DM) and type 2 diabetes mellitus (T2DM) among U.S. Medicaid pediatric population aged <18 years 2002 to 2016 by age, sex, and race/ethnicity. METHODS:Participants aged <18 years old from 2002 to 2016 were identified from the MarketScan Multi-State Medicaid Database. Diabetes was defined as having (a) ≥1 claims for an outpatient or inpatient diabetes diagnosis and ≥2 prescriptions for any anti-diabetes medications or (b) records of ≥2 claims for an outpatient or inpatient diabetes diagnosis that were at least 30 days apart. Annual prevalence of diabetes and 95% confidence intervals (CIs) were calculated. Age-, sex-, and race-stratified prevalence were also assessed. RESULTS: The annual prevalence of T1DM increased from 1.29 to 2.34/1000 pediatric persons from 2002 to 2016. The prevalence of T2DM rose from 0.70 in 2002 to 2.76/1000 in 2011, but then dropped to 2.12/1000 pediatric persons in 2016 in the Medicaid population. Prevalence of both T1DM and T2DM increased with age. While the prevalence of T1DM was similar in both sexes, and was most prevalent in Whites, prevalence of T2DM was higher in girls and was most prevalent in Blacks. CONCLUSIONS: While the annual prevalence of T1DM in pediatric persons enrolled in Medicaid increased continuously from 2002 to 2016, the annual prevalence of T2DM increased from 2002 to 2011, with a subsequent decrease in 2016, possibly because of the increase of relatively healthier participants with the expanded eligibility through the ACA between 2011 and 2016.
Authors: Jean M Lawrence; Jasmin Divers; Scott Isom; Sharon Saydah; Giuseppina Imperatore; Catherine Pihoker; Santica M Marcovina; Elizabeth J Mayer-Davis; Richard F Hamman; Lawrence Dolan; Dana Dabelea; David J Pettitt; Angela D Liese Journal: JAMA Date: 2021-08-24 Impact factor: 157.335
Authors: Xue Snow Feng; Ryan Farej; Bonnie B Dean; Fang Xia; Andrew Gaiser; Sheldon X Kong; Jay Elliott; Stefanie Lindemann; Rakesh Singh Journal: Kidney Med Date: 2021-11-03
Authors: Dianna J Magliano; Julian W Sacre; Jessica L Harding; Edward W Gregg; Paul Z Zimmet; Jonathan E Shaw Journal: Nat Rev Endocrinol Date: 2020-03-20 Impact factor: 43.330